New York, New York, United States The company was established in North America in United States. The main department of described VC is located in the New York.
Among the various public portfolio startups of the fund, we may underline Sutro Biopharma Among the most successful fund investment fields, there are Biotechnology, Medical. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund.
The overall number of key employees were 2.
The typical case for the fund is to invest in rounds with more than 10 participants. Despite the Nexthera Capital, startups are often financed by Skyline Ventures, SV Health Investors, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Vida Ventures, Tekla Capital Management, Surveyor Capital.
The top activity for fund was in 2018. The top amount of exits for fund were in 2018. The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is generally included in less than 2 deals every year.
Related Funds
| Fund Name | Location |
| Annex Ventures Management LLC | California, Los Altos, United States |
| ATA | Beijing, Beijing, China |
| Brinson Partners | Chicago, Illinois, United States |
| GRG Banking | China, Guangdong, Guangzhou |
| GuarantCo | - |
| IIFL Special Opportunities Fund | - |
| Kingsbridge Capital | England, London, United Kingdom |
| Monroe-Brown Biomedical Seed Fund | - |
| OpenSource Ventures | - |
| Pan Group Investments Pty Ltd | - |
| Park Avenue Capital | California, United States, Whittier |
| ReqMed Company | - |
| Rudin Ventures | - |
| Savitr Capital | California, San Francisco, United States |
| The Hodson Trust | - |
| The TCW Group | California, Los Angeles, United States |
| Unilazer Ventures | India, Maharashtra, Mumbai |
| Yunhe Partners | Beijing, Beijing, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 